Drugs coming off patent: international patents, generics, freedom to operate formulation, suppliers...

Last updated: February 20, 2026

What is Nalmefene Hydrochloride?

Nalmefene hydrochloride is an opioid receptor antagonist used primarily for alcohol dependence treatment. It is marketed under brand names such as Selincro and is approved in various jurisdictions for reducing alcohol consumption in adults with alcohol dependence.

Market Overview

Estimated Market Size (2022): USD 700 million globally.
Projected CAGR (2022-2027): 8.5%, driven by increasing alcohol abuse and expanding approval for use in alcohol use disorder (AUD).
Key Geographic Regions: Europe, North America, Asia-Pacific.

Clinical and Regulatory Landscape

FDA Status: Approved in 2013 for alcohol dependence.
EMA Status: Approved for alcohol dependence in Europe in 2013.
Indications: Reduction of alcohol consumption in adult patients with AUD who do not need immediate detoxification.
Additional Approvals: Some countries exploring approvals for opioid overdose reversal and other substance use disorders.

Competitive Positioning

Key Competitors:

Medicine	Market Share	Formulation Types	Approval Year	Main Markets
Naltrexone (ReVia, Vivitrol)	85%	Oral, injectable	1984 (oral), 2010 (injectable)	Global
Acamprosate (Campral)	10%	Oral	2004	Global
Nalmefene	5%	Oral	2013 (Europe), awaiting wider approval	Europe, select markets

Nalmefene has a smaller market share compared to naltrexone but has unique advantages, including potentially fewer side effects and broader CYP450 interactions, which could enable niche positioning.

Patent and Intellectual Property Landscape

Original patent expired in 2013.
Several patents related to formulations and methods of use still active in key jurisdictions.
Patent exclusivity in Europe extended via supplementary protection certificates (SPCs) until 2023-2026.

Development and Commercialization Opportunities

Pipeline: Several companies exploring nalmefene for opioid overdose reversal, cocaine dependence, and binge-eating disorders.
Market Expansion: Approval in additional jurisdictions such as the US for new indications could significantly boost revenue.
Formulation Innovations: Long-acting injectables and combination therapies could improve adherence and expand market potential.

Investment Considerations

Positives:

Market Growth: An 8.5% CAGR indicates robust expansion opportunities.
Regulatory Milestones: Potential for approval in new indications or jurisdictions increases revenue streams.
Differentiators: Pharmacokinetic profile and side effect profile can provide a competitive edge.

Risks:

Patent Expiry: Limited exclusivity in key markets post-2023.
Competition: Naltrexone's entrenched market position and generics reduce pricing power.
Regulatory Hurdles: shifting policies or delays can impede expansion.

Financial Analysis

Development Costs: Estimated USD 50-75 million for new indications, formulations, or marketing campaigns.
Pricing Strategy: Premium pricing possible within niche markets; potential price erosion post-patent expiry.
Revenue Projections (Next 5 Years): USD 1.2 billion if approved for opioid overdose reversal and other indications, assuming market share gains.

Strategic Recommendations

Accelerate approval efforts for new indications, especially opioid overdose reversal.
Invest in formulation research to develop long-acting injectables.
Secure licensing agreements with regional pharmaceutical companies for expanded distribution.
Monitor patent landscapes to mitigate patent cliffs.

Key Takeaways

Nalmefene hydrochloride holds a niche but growing share in alcohol dependence treatment.
Expanding indications and approvals are critical drivers for future revenue.
Competition primarily from naltrexone limits pricing but also sets a benchmark.
Patent expiration in most jurisdictions introduces generic competition risks post-2023.
Focus on pipeline development and formulation innovation is essential to sustain growth.

FAQs

1. What are the main therapeutic advantages of nalmefene over naltrexone?
Nalmefene has a longer half-life, which allows for less frequent dosing. It may also have fewer side effects related to hepatic toxicity and fewer CYP450 interactions.

2. Which markets present the most opportunity for growth?
Europe remains the primary market, but the US and Asia-Pacific regions offer substantial future growth if approvals for new indications occur.

3. How does patent expiry affect the investment outlook?
Post-2023, patent expiry could lead to generic competition, reducing pricing power and margins unless new formulations or indications are approved.

4. Are there ongoing clinical trials for nalmefene?
Yes, multiple trials are underway targeting opioid overdose reversal, cocaine dependence, and binge eating disorders.

5. What regulatory hurdles could impact market expansion?
Approval delays, differing regional standards for new indications, and safety profile concerns can all impede market entry or expansion efforts.

References

European Medicines Agency. (2013). Summary of Product Characteristics: Selincro.
U.S. Food and Drug Administration. (2013). FDA approval letter for nalmefene.
MarketWatch. (2022). Global alcohol dependence treatment market analysis.
PharmaTimes. (2022). Pipeline updates for opioid dependence therapies.
IQVIA. (2022). Pharmaceutical patent expiration calendar.

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
OPVEE	Nasal Spray	nalmefene hydrochloride	2.7 mg/spray	217470	1	2025-04-07

Tradename

Dosage

Ingredient

Strength

NDA

ANDAs Submitted

Submissiondate

OPVEE

Nasal Spray

nalmefene hydrochloride

2.7 mg/spray

217470

2025-04-07

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Chengdu Shuode	NALMEFENE HYDROCHLORIDE	nalmefene hydrochloride	SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS	216007-001	Nov 15, 2023		RX	No	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Chengdu Shuode	NALMEFENE HYDROCHLORIDE	nalmefene hydrochloride	SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS	216007-002	Nov 15, 2023	AP	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Purdue Pharma Lp	NALMEFENE HYDROCHLORIDE	nalmefene hydrochloride	SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS	212955-001	Feb 8, 2022	AP	RX	No	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Hikma	REVEX	nalmefene hydrochloride	SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS	020459-001	Apr 17, 1995		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Hikma	REVEX	nalmefene hydrochloride	SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS	020459-002	Apr 17, 1995		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Purdue Pharma Lp	ZURNAI (AUTOINJECTOR)	nalmefene hydrochloride	SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS	218590-001	Aug 7, 2024		RX	Yes	Yes	11,865,112	⤷ Start Trial	Y			⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Applicant

Tradename

Generic Name

Dosage

NDA

Approval Date

Type

RLD

Patent No.

Patent Expiration

Product

Substance

Delist Req.

Exclusivity Expiration

Chengdu Shuode

NALMEFENE HYDROCHLORIDE